Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROIC needs at least three reported quarters before a meaningful chart is shown.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Jyong Biotech Ltd. Ordinary Shares
Market Cap
$155.86M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$155.42M
Return on Invested Capital (ROIC)
-56.53%
TTM Avg
-185.89%
3Y Avg
-125.01%
5Y Avg
-88.85%
Market Cap
$158.30M
Return on Invested Capital (ROIC)
-13.94%
TTM Avg
-16.11%
3Y Avg
-25.11%
5Y Avg
-17.04%
Market Cap
$158.63M
Return on Invested Capital (ROIC)
-38.56%
TTM Avg
-39.74%
3Y Avg
-42.41%
5Y Avg
-37.88%
Market Cap
$152.17M
Return on Invested Capital (ROIC)
-165.56%
TTM Avg
-176.54%
3Y Avg
-127.81%
5Y Avg
-112.12%
Market Cap
$151.10M
Return on Invested Capital (ROIC)
-27.25%
TTM Avg
-49.08%
3Y Avg
-43.31%
5Y Avg
-52.54%
Market Cap
$151.10M
Return on Invested Capital (ROIC)
-23.41%
TTM Avg
-38.99%
3Y Avg
-40.72%
5Y Avg
-30.95%
Market Cap
$149.15M
Return on Invested Capital (ROIC)
-118.67%
TTM Avg
-87.91%
3Y Avg
-55.09%
5Y Avg
-41.64%
Market Cap
$162.20M
Return on Invested Capital (ROIC)
-57.59%
TTM Avg
-65.44%
3Y Avg
-58.20%
5Y Avg
-45.38%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares (MENS) | $155.86M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $155.42M | -56.53% | -185.89% | -125.01% | -88.85% |
| Inogen, Inc. (INGN)vs › | $158.30M | -13.94% | -16.11% | -25.11% | -17.04% |
| Minerva Neurosciences, Inc. (NERV)vs › | $158.63M | -38.56% | -39.74% | -42.41% | -37.88% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.17M | -165.56% | -176.54% | -127.81% | -112.12% |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.10M | -27.25% | -49.08% | -43.31% | -52.54% |
| Codexis, Inc. (CDXS)vs › | $151.10M | -23.41% | -38.99% | -40.72% | -30.95% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.15M | -118.67% | -87.91% | -55.09% | -41.64% |
| PepGen Inc. (PEPG)vs › | $162.20M | -57.59% | -65.44% | -58.20% | -45.38% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | -223.90% | -825.42% | -606.12% | -416.73% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2024-12-31 | -0.14% |
| 2024-09-30 | -0.15% |
